Arixon IV Injection
Arixon IV Injection is manufactured by Beximco Pharmaceuticals Ltd. Arixon IV Injection contains 1 gm/vial Ceftriaxone. It is Third generation Cephalosporins class drug.
Arixon IV is a sterile, semisynthetic, broad-spectrum, 3rd generation cephalosporin antibiotic for intravenous or intramuscular administration. The bactericidal activity of Arixon IV results from inhibition of cell wall synthesis. Arixon IV has a high degree of stability in the presence of beta-lactamases both penicillinases and cephalosporinases of gram-negative and gram- positive bacteria.
Arixon IV is used for the treatment of the following infections when caused by susceptible organisms:
Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, E. coli, Enterobacter aerogenes, Proteus mirabilis, Serratia marcescens.
Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains), Moraxella catarrhalis (including beta-lactamase producing strains).
Skin and Skin Structure Infections caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, E. coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis, Peptostreptococcus species.
Urinary Tract Infections (complicated and uncomplicated) caused by E. coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Klebsiella pneumoniae.
Uncomplicated Gonorrhea (cervical, urethral, pharyngial and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae.
Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae.
Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, E. coli, Haemophilus influenzae, Klebsiella pneumoniae.
Bone and Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, E. coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species.
Intra-abdominal Infections caused by E. coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species, Peptostreptococcus species.
Meningitis caused by Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae. Arixon IV has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis and E. coli.
Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of Arixon IV may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated.
|Brand Name:||Arixon IV|
|Therapeutic Class:||Third generation Cephalosporins|
|Manufacturer:||Beximco Pharmaceuticals Ltd|
|Last Updated:||November 21, 2020 at 6:15 pm|
Table Of contents
Arixon IV contains Ceftriaxone 1 gm/vial. Arixon IV Dosage:
Generally, Arixon IV should be taken once or equally devided twice a day for 4-14 days. Arixon IV therapy should be continued for at least 2 days after the sign and symptoms of infection have disappeared.
The usual duration of therapy is 4 to 14 days; in complicated infections longer therapy may be required. No dosage adjustment is required for patients with renal or hepatic impairment.
Use the solution immediately after reconstitution of powder.
Generally Arixon IV is well tolerated. However, few side effects including nausea, vomiting, diarrhea, dizziness and fever may occur.
Arixon IV should be administered with caution to individuals with a history of gastrointestinal disease, particularly colitis.
May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level with probenecid.
Pregnancy Lactation use
Pregnancy: The safety of Arixon IV in the treatment of infections during pregnancy has not been established. Arixon IV should only be used during pregnancy if the likely benefit outweighs the potential risk to the fetus and/or the mother.
Lactation: Arixon IV is excreted in breast milk at low concentrations. Therefore, caution should be exercised when Arixon IV is administered to a nursing mother.
Arixon IV should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics. It is contraindicated in premature infants during the first 6 weeks of life. Its safety in human pregnancy has not been established. Arixon IV is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium.
There is no specific antidote. Treatment of over dosage should be symptomatic.
Interaction with other Medicine
Store below 25°C, protected from light & moisture. Use reconstituted solutions immediately.
Reconstituted solutions are stable for 6 hours at room temperature and for 24 hours at 2°-8°C. It should not be mixed in the same syringe with any drug other than 1% Lidocaine Hydrochloride injection BP (for IM injection only).